What question did this study set out to answer?

The study aims to explore the implications of FDA approval of amyloid-β PET drugs to enhance patient selection for amyloid-β directed therapies in Alzheimer Disease.

February 22, 2026Open Access

Advancing Theranostics in Alzheimer Disease: FDA Approval of Amyloid-β PET Drugs for Selection of Patients for Amyloid-β–Directed Therapies and Other Labeling Updates

Puntos clave

The study aims to explore the implications of FDA approval of amyloid-β PET drugs to enhance patient selection for amyloid-β directed therapies in Alzheimer Disease.
Evaluation of FDA approval status for amyloid-β PET drugs
Analysis of theranostic approaches in Alzheimer Disease
Comparison with oncologic theranostic applications
FDA approved amyloid-β PET drugs for use in conjunction with therapies
Emphasis on targeting molecular markers for improved patient outcomes
Potential changes in clinical guidelines for Alzheimer's therapy based on these approvals

Resumen

Theranostics—the use of diagnostic and therapeutic drugs that target the same molecular marker of disease—extends beyond the paradigm of radiopharmaceutical drug pairs used in oncologic settings (e.g., somatostatin receptor subtype 2 and prostate-specific membrane antigen theranostics) to other

Me gusta

Guardar

Ver artículo completo